What can we do to improve SCID?
A rare disease affecting many babys around the world
Combined Immunodeficiencies or SCID is a devastating group of diseases by
which babies are
born without a
functioning immune system. No immune system means that they can
contract any infection or virus they are exposed to, without any means of
defending themselves against them. Babies born with SCID rarely survive beyond
their first year of life if they are not diagnosed and treated on time.
However, the disease can be cured if it is rapidly diagnosed and treated. A
first step to ensure this would be the inclusion of SCID screening in the
routine newborn screening national programmes in Member States. This is already
a reality for Norway, Iceland, Switzerland, Israel, United States or Taiwan.
Several EU countries are assessing its implementation in 2019 or 2020, but the
longer it takes, the greater the chances of losing babies’ lives due to this
As the Norwegian National Unit for Newborn Screening explains,
“we screen because
we can treat and
cure!”. Indeed, we are fortunate that SCID can be cured if
diagnosed and treated on time. Babies born with SCID can undergo a
hematopoietic stem cell transplant or receive gene therapy to try to correct
their defective immune system. A genetic therapy for a specific type of SCID
was the first-ever EU authorised gene therapy, and additional research in gene
therapy for SCID and primary immunodeficiencies is currently ongoing ! IPOPI is
involved in two EU funded research programmes (SCIDNET and RECOMB) aiming to
develop gene therapy for other types of SCID (covering up to 80% of SCID in
Diagnosis and research on new therapies that bring better health for patients can only have an impact if those therapies are available and accessible to patients. A big challenge today for the patient community, especially in the field of rare diseases, is to help reconcile the need for personalised medicine (most appropriate and effective for patients and, in the long term, cost-efficient) with short-term healthcare budget policies of EU governments.
IPOPI – International Patient Organisation for Primary Immunodeficiencies
The original article was published on Health First Europe.